"Prostatic Hyperplasia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Descriptor ID |
D011470
|
| MeSH Number(s) |
C12.294.565.500
|
| Concept/Terms |
Adenoma, Prostatic- Adenoma, Prostatic
- Adenomas, Prostatic
- Prostatic Adenomas
- Prostatic Adenoma
|
Below are MeSH descriptors whose meaning is more general than "Prostatic Hyperplasia".
Below are MeSH descriptors whose meaning is more specific than "Prostatic Hyperplasia".
This graph shows the total number of publications written about "Prostatic Hyperplasia" by people in this website by year, and whether "Prostatic Hyperplasia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 3 | 0 | 3 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 2 | 2 | 4 |
| 2003 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 3 | 0 | 3 |
| 2011 | 3 | 0 | 3 |
| 2012 | 2 | 0 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 4 | 0 | 4 |
| 2015 | 5 | 1 | 6 |
| 2016 | 8 | 0 | 8 |
| 2017 | 2 | 0 | 2 |
| 2018 | 2 | 2 | 4 |
| 2019 | 6 | 0 | 6 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
| 2022 | 3 | 0 | 3 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
| 2025 | 3 | 0 | 3 |
| 2026 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prostatic Hyperplasia" by people in Profiles.
-
Immune dysregulation in the prostates of C57BL/6Aire-/- mice mirrors that seen in human benign prostatic hyperplasia. J Pathol. 2026 Oct; 270(2):211-225.
-
Aquablation for LUTS due to BPH in men with localized prostate cancer. Can J Urol. 2026 Jun 26; 33(3):555-562.
-
Gaps in patient-reported outcome measures integration into the management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (LUTS/BPH): qualitative insights for implementation strategies. J Patient Rep Outcomes. 2026 Jun 12; 10(1).
-
Clinical outcomes of benign prostatic hyperplasia surgery in men with detrusor underactivity versus normal contractility: a systematic review and meta-analysis. Int Urol Nephrol. 2026 Oct; 58(10):4015-4025.
-
Immune cell single-cell RNA sequencing analyses link an age-associated T cell subset to symptomatic benign prostatic hyperplasia. Front Immunol. 2025; 16:1585446.
-
Benign Prostatic Hyperplasia and Sexual Dysfunction: Review of the Impact of New Medical and Surgical Therapies on Sexual Health. Curr Urol Rep. 2025 Jun 09; 26(1):49.
-
Infiltrating lipid-rich macrophage subpopulations identified as a regulator of increasing prostate size in human benign prostatic hyperplasia. Front Immunol. 2024; 15:1494476.
-
Enhanced clinical decisions for management of benign prostatic hyperplasia using patient-reported outcomes: protocol for a prospective observational study. BMC Urol. 2024 May 21; 24(1):110.
-
Increasing Role of the Advanced Practice Provider in Men's Health Clinics: An Analysis of Medicare and Commercial Claims in the United States. Urol Pract. 2023 07; 10(4):320-325.
-
The 10-item LURN Symptom Index (LURN SI-10) Detects Additional Symptoms and Shows Convergent Validity With the IPSS in Men Presenting With Lower Urinary Tract Symptoms. Urology. 2023 01; 171:184-189.